BEVERLY HILLS, Calif. - TelAve -- Xycota Biosciences, LLC ("Xycota"), an early-stage biotechnology company focused on brain repair therapeutics, today announced the formal unveiling of its neuro-restoration platform, anchored by newly published mechanistic evidence in the Nature Portfolio journal Neuropsychopharmacology.

The paper, "Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway" (Trezza, Hausman, et al., 2026), provides mechanistic evidence supporting the company's brain repair strategy: restoring synaptic function and neural circuitry by decoupling therapeutic effects from psychedelic receptor activity.

The "Big Unlock": Mechanistic Insight into Neural Repair

For decades, the therapeutic potential of psilocybin was assumed to be inseparable from its psychedelic effects. The Trezza-Hausman findings provide a strong translational rationale for challenging this paradigm. The research suggests that cognitive restoration may be mediated primarily through the BDNF/TrkB signaling pathway—the brain's intrinsic growth and repair circuitry—rather than hallucinogenic receptor pathways.

More on TelAve News

• Floor Kings Announces Official Launch of Premier Epoxy Flooring Services Across Arizona
• UK Buyers Purchase Luxury Home in Keene's Pointe, Windermere (Orlando, Florida)
• Instant IP Launches Rapid Takedown Service to Combat IP Theft, Deepfakes, and Copycat Websites
• Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
• Permian Museum Adds Photos of Fossils Discovered on a Meteorite

"This discovery is the bedrock of Xycota," said Dr. Marvin S. Hausman, MD, Founder and CSO. "We have identified a biological signaling pathway that triggers neural repair. Xycota was formed to translate this insight into a standardized biological interface, allowing us to engineer restorative therapeutics without the psychedelic effects."

The FTD-ALS Continuum: A Strategic Clinical Roadmap

With the BDNF-TrkB mechanism supported by preclinical data, Xycota is focusing its primary development program on Frontotemporal Dementia (FTD). FTD is a catastrophic condition characterized by the progressive decay of synaptic connections, leading to the loss of judgment, personality, and cognitive independence.

Strategically, Xycota's focus on FTD provides a critical entry point into a broader spectrum of neurodegenerative disorders. FTD and Amyotrophic Lateral Sclerosis (ALS) are increasingly recognized as part of a clinical and pathological continuum, often sharing underlying synaptic vulnerabilities and protein pathologies. By establishing a translational signal of repair in FTD, Xycota plans to expand its platform to address the urgent unmet needs in ALS and other disorders where synaptic degeneration is a primary driver of decay.

More on TelAve News

• This Saturday: Open House for Manalapan's Newest Single Family Home Community
• Radarsign™ Awarded Sourcewell Contract Expanding Access to Traffic Safety Solutions
• MainConcept and NETINT Bring VPU Acceleration to Easy Video API
• Larry R. Wasion's Jump Gate 2: Teleporter Expands the Time Travel Universe with High-Stakes Action and Ethical Dilemmas
• Bruce A. Rosenblat Releases A Pocket Full of Change, a Sharp, Thought-Provoking Book on Growth, Perspective, and Personal Change

Technology: Fungal-Derived Exosome Delivery

To translate these findings into a clinical reality, Xycota is developing a proprietary fungal-derived exosome delivery platform. This biological delivery vehicle is being engineered to improve CNS targeting and blood-brain barrier penetration, allowing for liver-bypass and more precise modulation of the BDNF pathway.

"Our goal is to move medicine from symptom management to the restoration of synaptic function," said Brad Listermann, President & Co-Founder. "By merging Dr. Hausman's 50-year track record in CNS development with this mechanistic evidence, Xycota is built to deliver a measurable signal of brain repair across multiple CNS disorders."

About Xycota Biosciences, LLC

Xycota Biosciences is an early-stage biotechnology company developing precision neuroplasticity therapeutics. Anchored by peer-reviewed science in the Nature Portfolio (Neuropsychopharmacology and npj Aging), Xycota is building a scalable translational platform to treat FTD, ALS, and mTBI through targeted synaptogenesis and neural repair.

For more information or to access the Strategic Data Room, visit https://xycota.com.